ADMS


Adamas Pharmaceuticals Inc (ADMS) Analyst Explains Why Osmotica’s FDA Approved Drug Isn’t a Viable Threat

Adamas Pharmaceuticals Inc (NASDAQ:ADMS) saw its shares crater by as much as 21% today on exceptionally high volume. This drop was triggered by …

Point72 Is Betting on Adamas Pharmaceuticals Inc (ADMS); Shares Soar

Adamas Pharmaceuticals Inc (NASDAQ:ADMS) is a mover and shaker out on the Street today, with investors sparking the stock on an almost 19% …

Mizuho Forecasts 127% Upside for Adamas Pharmaceuticals Inc (ADMS) Following Higher-Than-Anticipated Gocovri Pricing

Analyst nearly doubles price target between Gocovri pricing and better prospects in Multiple Sclerosis arena.

Adamas Pharmaceuticals Inc’ (ADMS) Gocovri Has Mizuho Confident Following Favorable Expert Call

Lead asset for ADMS indicates promising prospects in Parkinson’s along with valuable opportunity in MS.

Adamas Pharmaceuticals Inc Won FDA Approval; Shares Hit 52-Week High

Adamas Pharmaceuticals Inc (NASDAQ:ADMS) investors are busy throwing a party this evening, following the news that the drug maker has won FDA approval …

Adamas Pharmaceuticals Inc (ADMS) Shares Slip Ahead of PDUFA Date; Mizuho More Cautious

Adamas Pharmaceuticals Inc (NASDAQ:ADMS) saw its shares slipping nearly 17% this month ahead of the August 24 PDUFA date for ADS-5102 in the …